# IDEAYA Biosciences (IDYA) — News

IDYA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/idya/news

## Recent headlines

- [IDEAYA Biosciences, Inc.: Stifel resumes coverage with buy rating; price target $48](https://www.ainvest.com/news/ideaya-biosciences-stifel-resumes-coverage-buy-rating-price-target-48-2610) — AInvest Wire, Oct 14, 2026
- [IDEAYA Biosciences announces the promotion of Dr. Michael White to President, Research and Development](https://www.ainvest.com/news/ideaya-biosciences-announces-promotion-dr-michael-white-president-research-development-2609) — AInvest Wire, Sep 28, 2026
- [Ideaya Biosciences and Servier announce first patient dosed in optimum-11 global phase 3 registrational trial of darovasertib and crizotinib as adjuvant therapy for subjects with uveal melanoma](https://www.ainvest.com/news/ideaya-biosciences-servier-announce-patient-dosed-optimum-11-global-phase-3-registrational-trial-darovasertib-crizotinib-adjuvant-therapy-subjects-uveal-melanoma-2609) — AInvest Wire, Sep 9, 2026
- [Ideaya Biosciences, - To initiate phase 3 trial for IDE849 by year-end 2026 in ES-SCLC](https://www.ainvest.com/news/ideaya-biosciences-initiate-phase-3-trial-ide849-year-2026-es-sclc-2608) — AInvest Wire, Aug 31, 2026
- [Ideaya Biosciences announces clinical pact with Genentech](https://www.ainvest.com/news/ideaya-biosciences-announces-clinical-pact-genentech-2608) — AInvest Wire, Aug 19, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).